Why it matters
The finding may be relevant to research and treatment development for this lung-cancer group. The report does not establish that the drug is approved or available to patients in the United States.
RESEARCH & TREATMENTS • UNITED STATES
Novel drug nearly doubled progression-free survival in EGFR-mutated lung cancer study
This brief summarizes public reporting and official announcements. Research findings may be preliminary. Talk to a qualified clinician before making health decisions.
This event has left the current brief. The summary below describes the stored record; open the original sources for current conditions.
BLUF
A first-in-class antibody-drug conjugate nearly doubled progression-free survival compared with chemotherapy in patients with advanced EGFR-mutated non-small cell lung cancer whose disease had progressed after third-line treatment, MedPage Today reports. The article summary does not provide the study size, trial phase, or approval status.
HOW THIS BRIEF WAS MADE 1 outlet: 1 specialist. Automated sourcing and summaries by the BLUF engine. Corrections